| Title |
Chlamydia Screening in Women |
||
|---|---|---|---|
| CMS eCQM ID | CMS153v14 | CBE ID | Not Applicable |
| MIPS Quality ID | 310 | ||
| Measure Steward | National Committee for Quality Assurance | ||
| Description | Percentage of women 16-24 years of age who were identified as sexually active at any time during the measurement period and who had at least one test for chlamydia during the measurement period | ||
| Measure Scoring | Proportion | ||
| Measure Type | Process | ||
| Stratification | Report a total score, and each of the following strata:
Stratum 1: Patients age 16-20 by the end of the measurement period. Stratum 2: Patients age 21-24 by the end of the measurement period. |
||
| Risk Adjustment | None | ||
| Rationale | Chlamydia trachomatis is the most common sexually transmitted bacterial infection in the U.S., resulting in roughly 1.7 million cases (Centers for Disease Control and Prevention, 2019). Chlamydia infections are often asymptomatic, but, if left untreated, can lead to serious and irreversible complications (U.S. Preventive Services Task Force, 2021; Centers for Disease Control and Prevention, 2019).
Women are particularly vulnerable when infected with chlamydia. Left untreated, chlamydia can cause pelvic inflammatory disease (PID), which can lead to chronic pelvic pain or infertility. Pregnant women may also transmit the infection to their infant, potentially resulting in neonatal pneumonia (Centers for Disease Control and Prevention, 2019). |
||
Stay updated with the latest news regarding MACRA and MIPS
The Healthmonix Advisor is a free news source that connects you to the latest in the value-based care industry!